RS-2023-00218618

Discovery of Selective IRAK4 Degrader based on Protac Technology

College of Pharmacy, Gachon University

IMMUNOLOGY | Lead

Product Type	Small molecule
Indication	Lupus
Target	IRAK4
MoA(Mechanism of Action)	Blocking TLRs and IL-1R signaling by IRAK4 degradation
Competitiveness	• High IRAK4 degradation potency with DC50 values in single digit nanomolar ranges • Confirmed degradation mechanism: Ubiquitin-Proteasome pathway (UPS) • High degradation selectivity for CRBN neosubstrates • High MLM and HLM stability (> 80% remaining at 30 min), and mouse plasma stability (> 70% remaining at 120 min)
Development Stage	Lead
Route of Administration	Oral

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund